NO20073651L - Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi - Google Patents

Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi

Info

Publication number
NO20073651L
NO20073651L NO20073651A NO20073651A NO20073651L NO 20073651 L NO20073651 L NO 20073651L NO 20073651 A NO20073651 A NO 20073651A NO 20073651 A NO20073651 A NO 20073651A NO 20073651 L NO20073651 L NO 20073651L
Authority
NO
Norway
Prior art keywords
therapy
autoimmune disease
patients
antiangiogenesis
failed previous
Prior art date
Application number
NO20073651A
Other languages
English (en)
Norwegian (no)
Inventor
Sunil Agarwal
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20073651L publication Critical patent/NO20073651L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20073651A 2004-12-17 2007-07-16 Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi NO20073651L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63716904P 2004-12-17 2004-12-17
PCT/US2005/045600 WO2006066086A1 (en) 2004-12-17 2005-12-16 Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy

Publications (1)

Publication Number Publication Date
NO20073651L true NO20073651L (no) 2007-09-10

Family

ID=36177836

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073651A NO20073651L (no) 2004-12-17 2007-07-16 Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi

Country Status (23)

Country Link
US (2) US20060134111A1 (pt)
EP (1) EP1824885A1 (pt)
JP (1) JP2008524241A (pt)
KR (1) KR20070086218A (pt)
CN (1) CN101120020A (pt)
AR (1) AR052056A1 (pt)
AU (1) AU2005316403A1 (pt)
BR (1) BRPI0518105A (pt)
CA (1) CA2587932A1 (pt)
CR (1) CR9181A (pt)
IL (1) IL183347A0 (pt)
MA (1) MA29366B1 (pt)
MX (1) MX2007007165A (pt)
NO (1) NO20073651L (pt)
NZ (1) NZ555286A (pt)
PE (1) PE20061075A1 (pt)
RU (1) RU2007126970A (pt)
SG (1) SG158089A1 (pt)
SV (1) SV2006002342A (pt)
TN (1) TNSN07191A1 (pt)
TW (1) TW200634026A (pt)
WO (1) WO2006066086A1 (pt)
ZA (1) ZA200704898B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1637160A3 (en) * 1999-05-07 2006-05-03 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
CN1592645A (zh) * 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
LT2077282T (lt) * 2003-11-05 2017-03-10 Roche Glycart Ag Antigeną surišančios molekulės su padidintu fc receptoriaus surišimo giminingumu ir efektoriaus funkcija
DK2229956T3 (da) 2004-09-13 2013-07-29 Genzyme Corp Multimere konstruktioner
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors
TWI468417B (zh) * 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
EP2727996A1 (en) * 2008-11-06 2014-05-07 The Johns-Hopkins University Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors
NZ717213A (en) * 2008-12-09 2017-10-27 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CA2747937C (en) * 2008-12-23 2019-02-26 Merck Patent Gmbh Biomarkers for inhibitors with anti-angiogenic activity
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
JP5841072B2 (ja) 2010-02-10 2016-01-06 イミュノジェン・インコーポレーテッド Ｃｄ２０抗体およびその使用
PL2601214T3 (pl) 2010-08-06 2018-05-30 Genzyme Corporation Kompozycje antagonistyczne wobec VEGF oraz ich zastosowania
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
KR20160146747A (ko) * 2014-03-31 2016-12-21 제넨테크, 인크. 항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
DK3056216T3 (en) * 2015-02-11 2017-05-08 Deutsches Krebsforsch Cancer treatment with parvovirus combined with bevacizumab
AR114275A1 (es) 2018-03-09 2020-08-12 Agenus Inc Anticuerpos anti-cd73 y métodos de uso de los mismos
WO2023091887A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) * 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) * 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
IL85746A (en) * 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
US20040120950A1 (en) * 2002-12-20 2004-06-24 Kari Alitalo Modulation of VEGF-C/VEGFR-3 interactions in the treatment of rheumatoid arthritis
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences

Also Published As

Publication number Publication date
TW200634026A (en) 2006-10-01
EP1824885A1 (en) 2007-08-29
SV2006002342A (es) 2006-06-01
WO2006066086A1 (en) 2006-06-22
IL183347A0 (en) 2007-09-20
US20080214789A1 (en) 2008-09-04
JP2008524241A (ja) 2008-07-10
MX2007007165A (es) 2007-08-14
CN101120020A (zh) 2008-02-06
CA2587932A1 (en) 2006-06-22
US20060134111A1 (en) 2006-06-22
RU2007126970A (ru) 2009-01-27
NZ555286A (en) 2010-04-30
SG158089A1 (en) 2010-01-29
AR052056A1 (es) 2007-02-28
ZA200704898B (en) 2009-03-25
KR20070086218A (ko) 2007-08-27
CR9181A (es) 2008-07-31
MA29366B1 (fr) 2008-04-01
PE20061075A1 (es) 2006-11-15
TNSN07191A1 (en) 2008-11-21
AU2005316403A1 (en) 2006-06-22
BRPI0518105A (pt) 2008-11-04

Similar Documents

Publication Publication Date Title
NO20073651L (no) Antiangiogeneseterapi av autoimmunsykdom hos pasienter med mislykket tidligere terapi
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
NO20080084L (no) Molekyler som er i stand til a hemme bindingen mellom NGF og TrkA-reseptoren som analgetika med forlenget effekt
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
EA200901442A1 (ru) Комбинированная терапия соединением, проявляющим активность ингибитора рецептора адф на тромбоцитах
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
NO20060871L (no) Azepinderivater som farmasoytiske midler
NO20044562L (no) Fremgangsmater for behandling av tarmslyng
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
NO20080967L (no) Benzimidazoler nyttige som inhibitorer av proteinkinaser
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
NO20054371L (no) Somatostatin-dopamin kimaere analoger
BR112017007545A2 (pt) derivados de carbazol
NO20070502L (no) Azaindoler nyttige som inhibitorer av proteinkinaser
EA201591055A1 (ru) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
EA201691278A1 (ru) Замещенные пиперидинил-тетрагидрохинолины
EA201071146A1 (ru) Способы диагностирования, предупреждения и лечения болезней, связанных с костной массой
WO2007100430A3 (en) Cytisine and acetylcholine analogs and methods of treating mood disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application